See more : Vani Commercials Limited (VANICOM.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Xencor, Inc. (XNCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Xencor, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Limitless X Holdings Inc. (BLAB) Income Statement Analysis – Financial Results
- NOHO, Inc. (DRNK) Income Statement Analysis – Financial Results
- Sarda Energy & Minerals Limited (SARDAEN.NS) Income Statement Analysis – Financial Results
- Titanium Transportation Group Inc. (TTNMF) Income Statement Analysis – Financial Results
- HBT Financial, Inc. (HBT) Income Statement Analysis – Financial Results
Xencor, Inc. (XNCR)
About Xencor, Inc.
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 168.34M | 164.58M | 275.11M | 122.69M | 156.70M | 40.60M | 35.71M | 87.52M | 27.76M | 9.52M | 10.17M | 9.52M | 6.85M |
| Cost of Revenue | 253.60M | 8.80M | 7.49M | 169.80M | 118.59M | 97.50M | 71.77M | 51.87M | 34.14M | 18.52M | 17.00M | 12.67M | 0.00 |
| Gross Profit | -85.26M | 155.78M | 267.62M | -47.11M | 38.11M | -56.90M | -36.06M | 35.65M | -6.38M | -9.00M | -6.83M | -3.14M | 6.85M |
| Gross Profit Ratio | -50.65% | 94.65% | 97.28% | -38.39% | 24.32% | -140.13% | -100.98% | 40.73% | -22.97% | -94.50% | -67.13% | -33.01% | 100.00% |
| Research & Development | 253.60M | 199.56M | 192.51M | 169.80M | 118.59M | 97.50M | 71.77M | 51.87M | 34.14M | 18.52M | 17.00M | 12.67M | 12.66M |
| General & Administrative | 53.38M | 47.49M | 38.84M | 29.69M | 24.29M | 22.47M | 17.50M | 13.11M | 11.96M | 7.46M | 3.69M | 3.09M | 3.64M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 53.38M | 47.49M | 38.84M | 29.69M | 24.29M | 22.47M | 17.50M | 13.11M | 11.96M | 7.46M | 3.69M | 3.09M | 3.64M |
| Other Expenses | 0.00 | 27.97M | 38.86M | 7.46M | 13.36M | 8.96M | 4.17M | 2.08M | 746.00K | 44.00K | 31.00K | 86.00K | 65.00K |
| Operating Expenses | 306.98M | 247.05M | 231.34M | 199.49M | 142.88M | 119.97M | 89.27M | 64.98M | 46.10M | 25.98M | 20.69M | 15.75M | 16.30M |
| Cost & Expenses | 306.98M | 247.05M | 231.34M | 199.49M | 142.88M | 119.97M | 89.27M | 64.98M | 46.10M | 25.98M | 20.69M | 15.75M | 16.30M |
| Interest Income | 18.63M | 4.82M | 849.00K | 7.26M | 13.62M | 9.10M | 4.19M | 2.09M | 1.84M | 33.00K | 14.00K | 11.00K | 34.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.00K | 13.00K | 21.00K | 13.00K | 9.00K | 1.21M | 2.46M | 1.85M |
| Depreciation & Amortization | 11.50M | 8.80M | 7.49M | 5.79M | 4.30M | 3.25M | 2.03M | 1.47M | 1.11M | 882.00K | 711.00K | 527.00K | 607.00K |
| EBITDA | -125.87M | -72.16M | 51.26M | -71.00M | 18.12M | -75.88M | -40.70M | 45.86M | -16.47M | -15.53M | -58.34M | -5.61M | -8.75M |
| EBITDA Ratio | -74.77% | -50.11% | 15.91% | -62.59% | 8.82% | -195.48% | -149.99% | 25.75% | -66.05% | -172.41% | -103.12% | -58.86% | -127.70% |
| Operating Income | -138.64M | -82.47M | 43.77M | -76.80M | 9.53M | -79.37M | -53.56M | 22.54M | -18.34M | -16.46M | -10.52M | -6.23M | -9.45M |
| Operating Income Ratio | -82.36% | -50.11% | 15.91% | -62.59% | 6.08% | -195.48% | -149.99% | 25.75% | -66.05% | -172.87% | -103.42% | -65.41% | -138.01% |
| Total Other Income/Expenses | 18.20M | 27.97M | 38.86M | 7.46M | 13.36M | 8.96M | 4.17M | 2.08M | 746.00K | 35.00K | -49.74M | -2.36M | -1.75M |
| Income Before Tax | -120.44M | -54.51M | 82.63M | -69.33M | 27.19M | -70.41M | -49.39M | 24.62M | -17.59M | -16.42M | -60.26M | -8.59M | -11.20M |
| Income Before Tax Ratio | -71.55% | -33.12% | 30.04% | -56.51% | 17.35% | -173.41% | -138.30% | 28.13% | -63.37% | -172.50% | -592.39% | -90.24% | -163.57% |
| Income Tax Expense | 5.81M | 673.00K | -7.49M | -5.79M | 312.00K | 8.98M | -463.00K | 991.00K | -1.11M | -829.00K | 533.00K | 2.55M | 1.92M |
| Net Income | -126.09M | -55.18M | 82.63M | -63.54M | 26.88M | -70.41M | -48.93M | 23.63M | -17.59M | -16.42M | -60.26M | -8.59M | -11.20M |
| Net Income Ratio | -74.90% | -33.53% | 30.04% | -51.79% | 17.15% | -173.41% | -137.00% | 26.99% | -63.37% | -172.50% | -592.39% | -90.24% | -163.57% |
| EPS | -2.08 | -0.93 | 1.42 | -1.11 | 0.48 | -1.31 | -1.05 | 0.57 | -0.45 | -0.52 | -1.92 | -0.51 | -0.67 |
| EPS Diluted | -2.08 | -0.93 | 1.37 | -1.11 | 0.46 | -1.31 | -1.05 | 0.56 | -0.45 | -0.52 | -1.92 | -0.51 | -0.67 |
| Weighted Avg Shares Out | 60.50M | 59.65M | 58.38M | 57.21M | 56.53M | 53.75M | 46.82M | 41.27M | 39.02M | 31.39M | 31.35M | 16.69M | 16.69M |
| Weighted Avg Shares Out (Dil) | 60.50M | 59.65M | 60.50M | 57.21M | 58.47M | 53.94M | 46.82M | 42.39M | 39.02M | 31.43M | 31.35M | 16.69M | 16.69M |
7 Battered Stocks That Could TRIPLE by 2024
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Xencor Reports First Quarter 2023 Financial Results
Xencor Reports First Quarter 2023 Financial Results
Xencor to Host First Quarter 2023 Financial Results Webcast and Conference Call on May 8, 2023
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
Source: https://incomestatements.info
Category: Stock Reports
What is Xencor’s current cash position after the public offering?
Xencor (NASDAQ:XNCR) reported Q3 2024 financial results with revenues of $10.7 million, down from $59.2 million in Q3 2023. The company posted a net loss of $45.1 million, or $(0.71) per share. Cash position stood at $754.3 million after raising $201.3 million through a public offering.